Logo Image
|Articles|March 11, 2015

Five-Year Peak Sales Forecast of Newly Reimbursed Drugs in Japan Surges to $34bn

Author(s)News Update

March 11, 2015.

The overall output of the Japanese drug industry measured by expected peak sales potential of newly National Health Insurance (NHI)-reimbursed drugs surged to $34 billion between 2010-2014, up from $16.9 billion during 2005-2009, according to Evaluate’s new report, Japan Sales, Volume, Pricing 2015.   Highlights of the report include

  • Peak sales forecast of newly reimbursed drugs surged to $34 billion between 2010-14 compared to $16.9 billion during 2005-09.

  • Quantity of reimbursed drugs increased 8 percent to 64 in 2014 vs. 2013; peak sales forecasts increased 19 percent in 2014 to $6.3 billion.

  • The median reimbursed price for Japanese drugs between 2005-14 was 40 percent lower than the US; 20 percent lower than Germany.

  • New endocrine drugs have the highest peak sales potential with central nervous system drugs coming in second.

  • Median annual cost of new drugs jumped to $837 (¥95k) in 2010-14 from $697 (¥82k) in 2005-09.

The full version of the report can be downloaded at

www.evaluategroup.com/JapanSalesVolumePricing2015

.   

Related to this article

View more
How QMM Can Help the C-Suite See a $100 Million Problem Early
How QMM Can Help the C-Suite See a $100 Million Problem Early
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Read more